Claims
- 1. A compound of formula (I) ##STR16## and solvates thereof, in which R.sub.1 individually represents --OC(.dbd.O)C.sub.1-6 alkyl;
- R.sub.2 individually represents hydrogen, methyl which may be in the .alpha. or .beta. configuration or methylene;
- or R1 and R.sub.2 together represent ##STR17## wherein R.sub.5 and R.sub.6 are the same or different and each represents hydrogen or C.sub.1-6 alkyl;
- R.sub.3 and R.sub.4 are the same or different and each represents hydrogen or halogen; and
- represents a single or double bond.
- 2. A compound according to claim 1 in which R.sub.1 individually represents OC(.dbd.O)C.sub.1-3 alkyl.
- 3. A compound according to claim 1 or claim 2 in which R.sub.1 represents OC.dbd.(O)ethyl.
- 4. A compound according to claim 1 in which R.sub.1 represents OC(.dbd.O)ethyl.
- 5. A compound according to claim 1 in which R.sub.2 is methyl.
- 6. A compound according to claim 1 in which R.sub.1 and R.sub.2 together represent ##STR18## wherein R.sub.5 and R.sub.6 are the same or different and each represents hydrogen or C.sub.1-6 alkyl.
- 7. A compound according to claim 6 in which R.sub.5 and R.sub.6 are the same or different and each represents hydrogen or C.sub.1-3 alkyl.
- 8. A compound according to claim 6 in which R.sub.5 and R.sub.6 are the same or different and each represents hydrogen, methyl or n-propyl.
- 9. A compound according to claim 6 in which R.sub.5 and R.sub.6 are both methyl.
- 10. A compound according to claim 6 in which R.sub.5 and R.sub.6 are different and each represents hydrogen or n-propyl.
- 11. A compound according to claim 1 in which R.sub.3 and R.sub.4 are the same or different and each represents hydrogen, fluorine or chlorine.
- 12. A compound according to claim 1 in which R.sub.3 and R.sub.4 are the same or different and each represents hydrogen or fluorine.
- 13. A compound according to claim 1 in which R.sub.3 and R.sub.4 are both fluorine.
- 14. A compound according to claim 1 in which R.sub.1 individually represents OC(.dbd.O) C.sub.1-6 alkyl; R.sub.2 is methyl; R.sub.3 and R.sub.4 are the same or different and each represents hydrogen or fluorine; and represents a single or a double bond.
- 15. A compound according to claim 14 in which R.sub.1 individually represents OC(.dbd.O) ethyl and R.sub.3 and R.sub.4 are both fluorine.
- 16. A compound according to claim 1 in which R.sub.1 and R.sub.2 together represent ##STR19## wherein R.sub.5 and R.sub.6 are the same or different and each represents hydrogen or C.sub.1-6 alkyl; R.sub.3 and R.sub.4 are the same or different and each represents hydrogen or fluorine; and represents a single or a double bond.
- 17. A compound according to claim 15 in which R.sub.5 and R.sub.6 are the same or different and each represents hydrogen, methyl or n-propyl and R.sub.3 and R.sub.4 are both fluorine.
- 18. A compound according to claim 1 in which S is bonded to the alpha carbon atom of the lactone moiety.
- 19. A compound according to claim 1 in which S is bonded to the beta carbon atom of the lactone moiety.
- 20. 6.alpha.,9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.-methyl-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-17.alpha.-propionyloxy-pregn-4-ene-3,20-dione;
- 16.alpha.,17.alpha.-(R-Butylidenedioxy)-6.alpha.,9.alpha.-difluoro-11.beta.-hydroxy-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- 16.alpha.,17.alpha.-Butylidenedioxy-11.beta.-hydroxy-21-(2-oxo-tetrahydrofuran-3-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- .alpha. . 9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropylidenedioxy-21-(2-oxo-tetrahydro-furan-5-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- 9.alpha.-Fluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropylidenedioxy-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- 9.alpha.-Fluoro-11.beta.-hydroxy-16.beta.-methyl-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-17.alpha.-propionyloxy-pregna-1,4-diene-3,20-dione;
- and solvates thereof.
- 21. 6.alpha.,9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.-methyl-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-17.alpha.-propionyloxy-pregna-1,4-diene-3,20-dione;
- and solvates thereof.
- 22. 6.alpha.,9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropylidenedioxy-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- and solvates thereof.
- 23. 6.alpha.,9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropylidenedioxy-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-pregn-4-ene-3,20-dione;
- and solvates thereof.
- 24. 6.alpha.,9.alpha.-Difluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropylidenedioxy-21-(2-oxo-tetrahydro-furan-4-yl-sulfanyl)-pregna-1,4-diene-3,20-dione;
- and solvates thereof.
- 25. 16.alpha.,17.alpha.-(R-Butylidenedioxy)6.alpha.,9.alpha.-difluoro-11.beta.-hydroxy-21-(2-oxo-tetrahydro-furan-4-yl-sulfanyl)-pregn-4-ene-3,20-dione;
- and solvates thereof.
- 26. 16.alpha.,17.alpha.-(R-Butylidenedioxy)-6.alpha.,9.alpha.-difluoro-11.beta.-hydroxy-21-(2-oxo-tetrahydro-furan-3-yl-sulfanyl)-pregn-4-ene-3,20-dione;
- and solvates thereof.
- 27. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof, together, in admixture with one or more physiologically acceptable diluents or carriers.
- 28. A pharmaceutical aerosol formulation comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon as propellant, optionally in combination with a surfactant and/or a co-solvent.
- 29. A composition comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof and another therapeutically active agent.
- 30. A composition according to claim 29 in which said another therapeutically active agent is a .beta..sub.2 -adrenoreceptor agonist.
- 31. A method for the treatment of a human or animal subject with an inflammatory and/or allergic disorder, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof.
- 32. A process for preparing a compound of formula (I) as claimed in claim 1, comprising:
- A. reacting a compound of formula (II) ##STR20## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and are defined in claim 1 and L represents an appropriate leaving group or L represents a halogen
- with a compound of formula III ##STR21## and salts thereof; B. reacting a compound of formula (IV) ##STR22## and salts thereof, with a compound of formula (V) or formula (VI) ##STR23## wherein Z represents a leaving group.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9526630 |
Dec 1995 |
GBX |
|
9613036 |
Jun 1996 |
GBX |
|
Parent Case Info
This application is a 371 of PCT/GB96/03153 filed Dec. 19, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/GB96/03153 |
12/19/1996 |
|
|
6/24/1998 |
6/24/1998 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/24367 |
7/10/1997 |
|
|
Non-Patent Literature Citations (2)
Entry |
Chemical & Pharmaceutical Bulletin, 37(12), Dec. 1989, Japan pp. 3286-3293 XP002026042 Mitsukuchi et al. |
Chemical & Pharmaceutical Bulletin, 37 (7), Jul. 1989, Japan pp. 1795-1801 XP002026043 Mitsukuchi et al. |